- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00513903
Expanding the Role of Pharmacists in Treating Persons With Cardiovascular or Lung Diseases (IowaCOC)
Enhanced Continuity of Pharmacy Care for Cardiovascular or Pulmonary Diseases
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Drugs used to treat cardiovascular and lung diseases are the most frequent cause of hospitalizations and emergency department visits related to inadequate therapy or ADEs. ADEs occur in 25% of patients who are able to walk and may cause up to 17% of hospital admissions among the elderly. A lack of communication and coordination between the hospital setting and the patient's own community setting, upon patient discharge, may contribute to the high number of ADEs. By expanding the role of pharmacists and encouraging communication between hospitals and pharmacists, the number of ADEs may be reduced. There have been a few small studies that have examined the way patient information is transferred between hospital and community pharmacists, but these studies did not involve the patients' primary care physicians nor did they fully evaluate the effect of communication between hospital and community pharmacists. The purpose of this study is to evaluate the effectiveness of providing a pharmacist case manager to hospitalized patients with cardiovascular or lung disease at reducing the number of ADEs, re-hospitalizations, and unscheduled medical visits.
This study will enroll individuals with certain conditions or diseases who are admitted to the hospital. Participants will be randomly assigned to either a control group, a minimal treatment group, or an enhanced treatment group. Participants in the minimal and enhanced treatment groups will meet with a pharmacist case manager while in the hospital to conduct a medication history review. The case manager will also meet with participants at the time of hospital discharge and provide them with a discharge summary and educational materials. Additionally, for participants in the enhanced treatment group, the case manager will do the following: transfer the discharge summary data to the participant's community physician and pharmacist; call the participant 3 to 5 days following discharge from the hospital and as needed thereafter to resolve medication problems; and communicate with and make recommendations to the participant's community physician and pharmacist. All participants will meet with a study research nurse immediately after study entry to complete questionnaires. Study nurses will also call all participants 30 and 90 days following hospital discharge to collect adverse event information. Surveys will be completed by each participant's pharmacist and primary care physician 90 days following the participant's discharge from the hospital.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- The University of Iowa
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Speaks either English or Spanish
- Willing to obtain all long-term prescriptions from one community pharmacy during the 90-day study period
- Diagnosed with at least one of the following conditions: high blood pressure, hyperlipidemia, heart failure, coronary artery disease, heart attack, stroke, transient ischemic attack, asthma, chronic obstructive pulmonary disease (COPD), diabetes, or receiving oral anticoagulation therapy
- Admitted to the general medicine, family medicine, cardiology, or orthopedics services hospital department
Exclusion Criteria:
- Does not have a working telephone
- Has a hearing impairment that does not allow the use of a telephone
- Enrolled in Iowa Care (i.e., individual has no community physician or community pharmacist following hospital discharge)
- Life expectancy estimated at less than 6 months at the time of study entry
- Dementia or cognitive impairment
- Severe psychiatric or psychosocial factors, including substance abuse, that may impair the desire or ability to complete all aspects of the study
- Admission to the psychiatric, surgery, or hematology/oncology services hospital department
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Minimal intervention
Minimal intervention group patients will be seen by a clinical pharmacist in the hospital but will not receive followup after hospital discharge.
|
Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
|
Experimental: Enhanced intervention
Enhanced intervention patients will receive care from a clinical pharmacist during hospitalization and followup by phone after hospitalization.
|
Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
|
Sin intervención: Control
Control arm patients will not be seen by the clinical pharmacist.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
ADEs
Periodo de tiempo: Measured 30 and 90 days after hospital discharge
|
Measured 30 and 90 days after hospital discharge
|
Medication appropriateness
Periodo de tiempo: Measured 30 and 90 days after hospital discharge by the Hanlon et al. Medication Appropriateness Index
|
Measured 30 and 90 days after hospital discharge by the Hanlon et al. Medication Appropriateness Index
|
Complications related to medications, including the number of hospital readmissions, unscheduled visits to emergency departments or urgent care facilities, and physician visits related to a medication problem or ADE
Periodo de tiempo: Measured 30 and 90 days after hospital discharge
|
Measured 30 and 90 days after hospital discharge
|
Cost-effectiveness of the minimal or enhanced treatment compared to usual care
Periodo de tiempo: Measured 30 and 90 days after hospital discharge
|
Measured 30 and 90 days after hospital discharge
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Number of medications
Periodo de tiempo: Measured 30 and 90 days after hospital discharge
|
Measured 30 and 90 days after hospital discharge
|
Complete medication list
Periodo de tiempo: Measured 30 and 90 days after hospital discharge
|
Measured 30 and 90 days after hospital discharge
|
Community physician and pharmacist surveys
Periodo de tiempo: Measured 90 days after participant's hospital discharge
|
Measured 90 days after participant's hospital discharge
|
Medication adherence
Periodo de tiempo: Measured 30 and 90 days after hospital discharge
|
Measured 30 and 90 days after hospital discharge
|
Barriers to patient adherence
Periodo de tiempo: Measured at baseline by scores on the following questionnaires: self-efficacy, cognitive impairment (Pfeiffer Mental Status Questionnaire), medication management skills and the Katz index of activities of daily living
|
Measured at baseline by scores on the following questionnaires: self-efficacy, cognitive impairment (Pfeiffer Mental Status Questionnaire), medication management skills and the Katz index of activities of daily living
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Barry L. Carter, PharmD, University of Iowa
Publicaciones y enlaces útiles
Publicaciones Generales
- Carter BL, Farris KB, Abramowitz PW, Weetman DB, Kaboli PJ, Dawson JD, James PA, Christensen AJ, Brooks JM. The Iowa Continuity of Care study: Background and methods. Am J Health Syst Pharm. 2008 Sep 1;65(17):1631-42. doi: 10.2146/ajhp070600.
- Farley TM, Shelsky C, Powell S, Farris KB, Carter BL. Effect of clinical pharmacist intervention on medication discrepancies following hospital discharge. Int J Clin Pharm. 2014 Apr;36(2):430-7. doi: 10.1007/s11096-014-9917-x. Epub 2014 Feb 11.
- Israel EN, Farley TM, Farris KB, Carter BL. Underutilization of cardiovascular medications: effect of a continuity-of-care program. Am J Health Syst Pharm. 2013 Sep 15;70(18):1592-600. doi: 10.2146/ajhp120786.
- Anderegg SV, Demik DE, Carter BL, Dawson JD, Farris K, Shelsky C, Kaboli P. Acceptance of recommendations by inpatient pharmacy case managers: unintended consequences of hospitalist and specialist care. Pharmacotherapy. 2013 Jan;33(1):11-21. doi: 10.1002/phar.1164.
- Farris KB, Carter BL, Xu Y, Dawson JD, Shelsky C, Weetman DB, Kaboli PJ, James PA, Christensen AJ, Brooks JM. Effect of a care transition intervention by pharmacists: an RCT. BMC Health Serv Res. 2014 Sep 18;14:406. doi: 10.1186/1472-6963-14-406.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 498
- R01HL082711 (Subvención/contrato del NIH de EE. UU.)
- R01HL082711-01A2 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedades cardiovasculares
-
Mayo ClinicInscripción por invitaciónRiesgo cardiovascular | Prevención cardiovascularEstados Unidos
-
University of DelawareReclutamientoFactor de riesgo cardiovascular | Salud cardiovascularEstados Unidos
-
Oregon Health and Science UniversityTerminadoEnfermedad cardiovascular | Factores de riesgo cardiovascularEstados Unidos
-
Medical College of WisconsinReclutamientoEnfermedades cardiovasculares | Factor de riesgo cardiovascular | Salud cardiovascularEstados Unidos
-
Hospital Mutua de TerrassaTerminadoEnfermedad cardiovascular | Factor de riesgo cardiovascularEspaña
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityTerminadoEnfermedad cardiovascular | Influencia psicosocial en la enfermedad cardiovascularEstados Unidos
-
Medical College of WisconsinTerminadoEnfermedades cardiovasculares | Factores de riesgo cardiovascular | Salud cardiovascular | Impacto del cantoEstados Unidos
-
Centre Hospitalier Universitaire DijonTerminadoPacientes de Alto Riesgo Cardiovascular | Pacientes de bajo riesgo cardiovascularFrancia
-
Shanghai 10th People's HospitalDesconocidoPresión arterial | Factor de riesgo cardiovascular | Mortalidad global | Mortalidad cardiovascular | Eventos cardiovasculares | Daño al órgano dianaPorcelana
-
Methodist Health SystemTerminado
Ensayos clínicos sobre Minimal intervention
-
University of OxfordOxford University Hospitals NHS TrustDesconocidoSíntomas de comportamientoReino Unido
-
Shiraz University of Medical SciencesTerminado
-
Heidelberg UniversityDesconocidoRetraso de idioma | Trastornos del desarrollo del lenguajeAlemania
-
Munich Municipal HospitalTechnical University of Munich; University of RegensburgDesconocido
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR)Activo, no reclutandoDependencia a la nicotina, cigarrillos | Abstinencia de nicotinaCanadá
-
IWK Health CentreCanadian Institutes of Health Research (CIHR)TerminadoTrastorno de oposición desafiante | Trastorno de conductaCanadá
-
The Hospital for Sick ChildrenTerminadoObesidad infantilCanadá
-
VA Office of Research and DevelopmentTerminadoTrastornos de Estrés PostraumáticoEstados Unidos
-
IWK Health CentreMcGill University; Canadian Institutes of Health Research (CIHR); University of... y otros colaboradoresActivo, no reclutandoTrastornos del neurodesarrollo | Trastornos del ComportamientoCanadá
-
Sahlgrenska University Hospital, SwedenKarolinska University Hospital; Skane University Hospital; Karlstad Central Hospital y otros colaboradoresActivo, no reclutandoClaudicación intermitenteSuecia